Skip to main content
Charles Loprinzi, MD, Oncology, Rochester, MN

CharlesLLoprinziMD

Oncology Rochester, MN

Professor of Medicine, Mayo Medical School

Dr. Loprinzi is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Loprinzi's full profile

Already have an account?

  • Office

    200 1st St Sw
    Mayo Clinic, Dept Med Oncology
    Rochester, MN 55905
    Phone+1 507-284-2511

Education & Training

  • University of Wisconsin Hospitals and Clinics
    University of Wisconsin Hospitals and ClinicsFellowship, Medical Oncology, 1982 - 1984
  • Creighton University School of Medicine/Maricopa Medical Center (Phoenix)
    Creighton University School of Medicine/Maricopa Medical Center (Phoenix)Residency, Internal Medicine, 1979 - 1982
  • Oregon Health and Science University School of Medicine
    Oregon Health and Science University School of MedicineClass of 1979

Certifications & Licensure

  • MN State Medical License
    MN State Medical License 1985 - 2025
  • AZ State Medical License
    AZ State Medical License 1988 - 2017
  • FL State Medical License
    FL State Medical License 1987 - 2005
  • WI State Medical License
    WI State Medical License 1982 - 1985
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • America's Top Doctors Castle Connolly, 2003-2014
  • America's Top Doctors for Cancer Castle Connolly, 2005-2013
  • Fellow (FASCO) American Society of Clinical Oncologists, 2008

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • The Importance of a Cause-Based Protocol to Approach Cancer-Related Nausea and Vomiting—Reply  
    Charles L Loprinzi, Rudolph M Navari, JAMA Oncology
  • Olanzapine for the Treatment of Advanced Cancer–Related Chronic Nausea and/or Vomiting  
    Rudolph M Navari, Costantine Albany, Charles L Loprinzi, JAMA Oncology

Lectures

  • Scrambler therapy for established chemotherapy-induced neuropathy: A randomized phase II trial. 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
  • Mayo Clinic Oncology Review 
    Mayo School of Continuous Professional Development, Minneapolis, Minnesota - 7/20/2013
  • MSCO Fellows Dinner Meeting 
    Minnesota Society of Clinical Oncology (MSCO), Minneapolis, Minnesota - 7/20/2013
  • Join now to see all

Other

Authored Content

  • Olanzapine for the Treatment of Advanced Cancer–Related Chronic Nausea and/or VomitingMay 2020
  • Olanzapine for the Treatment of Advanced Cancer–Related Chronic Nausea and/or VomitingMay 2020

Press Mentions

  • Charles B. Hammond, M.D.,
    Charles B. Hammond, M.D.,September 30th, 2024
  • ASCO Voices 2020
    ASCO Voices 2020August 9th, 2020
  • What Is Peripheral Neuropathy and How Can It Be Prevented or Treated?
    What Is Peripheral Neuropathy and How Can It Be Prevented or Treated?July 14th, 2020
  • Join now to see all

Grant Support

  • Survivorship Research Established Investigator AwardNational Cancer Institute2008–2011
  • Statistical Support UnitNational Cancer Institute2007–2011
  • Nursing And PharmacyNational Cancer Institute2007–2011
  • Community Clinical Oncology ProgramNational Cancer Institute2004–2011
  • SupplementNational Cancer Institute2007–2008
  • Operations UnitNational Cancer Institute2007
  • CapitationNational Cancer Institute2007
  • AuditNational Cancer Institute2007
  • AdministrationNational Cancer Institute2007
  • Ncctg CCOP Research Base - Foreign AccrualNational Cancer Institute2006
  • Community Clinical Oncology Program - Foreign AccrualNational Cancer Institute2005
  • Ncctg Foreign AccrualsNational Cancer Institute2004
  • Foreign Accural - NcctgNational Cancer Institute2003
  • Cancer Chemoprevention--Role Of Infection/ImmunityNational Cancer Institute1999–2003
  • Community Clinical Oncology ProgramNational Cancer Institute1994–2003
  • Inhibition Of Ornithine Decarboxylase By Oral CompoundsNational Cancer Institute1985

Professional Memberships